Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2017
At a glance
- Drugs ZW 25 (Primary)
- Indications Cancer; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Zymeworks
- 05 Dec 2017 According to a Zymeworks media release, the dose escalation portion of the study enrolled 22 patients, Enrollment is underway for the second part of the study utilizing ZW25 every other week at 20 mg/kg in four expansion cohorts. The company plans to provide an update on the expansion cohort portion of the trial at the American Society of Clinical Oncology Annual Meeting in 2018.
- 05 Dec 2017 According to a Zymeworks media release, results from the dose escalation portion of the study have been presented at the San Antonio Breast Cancer Symposium.
- 05 Dec 2017 Results from the dose escalation portion of the study published in Zymeworks media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History